The peroxisome proliferator-activated receptors (PPARa, PPARg and PPARd) are a set of ligand-activated transcription factors in the nuclear hormone receptor superfamily. [1] [2] [3] [4] These receptors regulate the expression of a large number of genes involved in lipid metabolism and energy balance by binding to a DNA sequence termed PPAR response elements.
These receptors regulate the expression of a large number of genes involved in lipid metabolism and energy balance by binding to a DNA sequence termed PPAR response elements.
5) The PPARg is predominantly expressed in adipose tissues, and plays a pivotal role in adipose differentiation, and the regulation of glucose and lipid homeostasis. The clinically useful thiazolidinedione (TZD) class of insulin sensitizers such as rosiglitazone 6) and pioglitazone 7) ( Fig. 1 ) are potent PPARg agonists used in the treatment of Type 2 diabetes. TZDs are known to improve insulin resistance, which is a key underlying feature of Type 2 diabetes 8) ; however, the use of TZDs has been limited because of their serious side effects such as hepatic toxicity, weight gain and edema. Meanwhile, PPARa is highly expressed in metabolically active tissues such as the liver, heart and muscle, and regulates lipid homeostasis. PPARa agonists such as clofibrate ( Fig. 1 ) have demonstrated the ability to reduce serum triglyceride and increase HDL cholesterol levels, 9) and are being utilized as hypolipidemic agents. In addition, recent studies revealed that dual agonists of PPARa/g decrease the free triglyceride plasma concentration and increase plasma HDL concentration in an insulin-resistant animal model. 10, 11) Thus, many groups have ongoing research programs to identify more potent and less toxic PPARa agonists, PPARg agonists and PPARa/g dual agonists.
We previously reported compound 1 ( Fig. 1) , which was designed based on the structure of rosiglitazone and 15d-PGJ 2 , 12, 13) as a potent PPARg ligand. 14) To find more potent PPARg agonists and novel PPARa agonists, we chose compound 1 as the lead structure, because recent reports indicated that PPARg affinity can be increased by the introduction of substituents into the C-2 position of propanoic acid, [15] [16] [17] [18] [19] and minor structural modifications can convert PPAR subtype selectivity. [20] [21] [22] In this article, we report the synthesis, binding affinity and biological activity of PPAR ligands based on the structure of compound 1.
Chemistry The compounds prepared for this study are shown in Fig. 2 , and the routes used for synthesis are shown in Charts 1-3. Chart 1 shows the preparation of compounds 1, 3, 4, 6-10, 12 and 13. The 2-nonylaminopyridine 18 was prepared by the method of Buchwald 23) : treatment of n-nonylamine 17 with 2-bromopyridine, Pd 2 (DBA) 3 , BINAP, and tBuONa in toluene at 105°C. p-Hydroxybenzaldehyde 19a, m-hydroxybenzaldehyde 19b and isovaniline 19c were allowed to react with 1,2-dibromoethane to give ethers 20a-c. The Horner-Wadsworth-Emmons reaction 24) was applied to the conversion of 20a-c into acrylic acid ethyl esters 21a- 7, 2007 ; published online May 9, 2007 j. The double bonds of 21a-j were hydrogenated to yield compounds 22a-j. Coupling between 2-nonylaminopyridine 18 and propanoic acid ethyl esters 22a-j afforded N-(2-pyridinyl)-N-nonylpropanoic acid ethyl esters 23a-j. The subsequent hydrolysis of 23a-j gave the desired carboxylic acids 1, 3, 4, 6-10, 12 and 13.
Synthesis and Evaluation of 2-Nonylaminopyridine Derivatives as PPAR Ligands
The preparation of compounds 2, 5, 11 and 14, which have one or two methyl groups at the C-2 position of propanoic acid, is outlined in Chart 2. Aldehydes 20a and 20c were reduced by NaBH 4 and allowed to react with acetic anhydride to give 25a and 25b. Compounds 25a and 25b were treated with 1-methoxy-1-trimethylsilyloxypropene or dimethylketene methyltrimethylsilyl acetal in the presence of magnesium perchlorate in anhydrous CH 2 Cl 2 to give esters 26a-d. 25) Coupling between 2-nonylaminopyridine 18 and propanoic acid methyl esters 26a-d afforded N-(2-pyridinyl)-N-nonyl compounds 27a-d and subsequent hydrolysis gave carboxylic acids 2, 5, 11 and 14.
Preparation of the acrylic acid derivatives 15 and 16 is shown in Chart 3. Acrylic acid ethyl esters 21a and 21h were allowed to react with 2-nonylaminopyridine 18 to give compounds 28a and 28b. Treatment of 28a and 28b with aqueous NaOH gave N-(2-pyridinyl)-N-nonyl acrylic acids 15 and 16.
Results and Discussion
The binding affinity of the compounds for PPARs was evaluated with the CoA-BAP System (Microsystems). 26) In this system, alkaline phosphatase (AP) activity is directly proportional to the affinity of the ligands for PPARs. The abilities of compounds 1-16 to bind PPARa, PPARg and PPARd were evaluated and the results are shown in Figs. 3, 4 and 5, respectively. GW7647 27) (PPARa), rosiglitazone 6) (PPARg) and GW501516 28) (PPARd) were used as reference compounds (Fig. 1) .
The lead compound 1 showed relatively high affinity for PPARg and little affinity for PPARa and PPARd (Fig. 3-5 ). We initially examined the effect of substituents at the C-2 position of the propanoic acid of 1, because it has been reported that the introduction of an alkyl or an alkoxy group at this position increases the activity of PPARg and PPARa. [15] [16] [17] [18] [19] Among compound 1, methyl 2, ethyl 3, ethoxy 4, and dimethyl 5, compound 4 showed the strongest affinity for PPARg, so compound 4 was founded to be a potent and selective PPARg ligand (Figs. 3-5 ). In addition, the PPARg affinity of compound 3 was comparable to that of compound 1, whereas compound 3 displayed strong affinity for PPARa as compared with 1 (Figs. 3, 4) .
Next, we investigated the PPARs affinity of compound 6, the meta isomer of compound 1. 29) Compound 6 showed much higher affinity for PPARa than 1 (Fig. 4) . Furthermore, the affinity for PPARg of 6 was lower than that of 1 (Fig. 3) , and compound 6 exhibited little affinity for PPARd (Fig. 5 ). To find more potent PPARa ligands, we prepared and tested compounds 7, 8 and 9 in which a methyl, ethyl and ethoxy group was substituted at the C-2 position of the propanoic acid of 6, respectively. Compounds 7 and 8 showed strong affinity for PPARa and compound 8 displayed slightly weak affinity for PPARg as compared with the parent compound 6. The effect of the introduction of a methoxy group at the C-4 position of the benzene ring of 6 was also investigated; however, compounds 10-14 showed no pronounced affinity for PPARs as compared to compound 6 (Figs. 3-5).
The acrylic acid derivatives 15 and 16 did not show notable affinity for PPARs (Figs. 3-5).
Based on the findings in the binding assay, we next investigated the PPAR transactivation activity of compounds 1, 3, 4, 6, 7, and 8 by reporter gene assay 30) (Table 1) . We initially tested the activity of compound 1, which did not show significant transcriptional activity for PPARa, d, and g. We then examined the activity of compounds 3 and 4, which have an ethyl or ethoxy group at the C-2 position of the propanoic acid of 1. As expected from the binding assay, compound 3 was a PPARa/g dual agonist. Although the binding assay indicated that compound 4 is a selective PPARg ligand, it showed potent dual-agonist activity toward PPARa and PPARg. Compound 6, the meta isomer of compound 1, was found to be a triple agonist. Compound 7, which had an introduced methyl group at the C-2 position of the propanoic acid moiety of 6, improved the EC 50 values and selectivity for PPARa and PPARg, and the introduction of ethyl group (compound 8) increased the activity and selectivity for PPARa. Among these compounds, compound 8 showed the highest selectivity for PPARa.
As compounds 3 and 4 were found to have relatively high PPARg agonist activity in our study, we used them for further evaluation. Since it has been reported that the activation of PPARg enhances adipocyte differentiation 31) and increases insulin sensitivity, compounds 3 and 4 were subjected to a human hypodermic preadipocyte differentiation test.
32) The accumulation of triglycerides in the cells was observed after the administration of compounds 3 and 4 at concentrations of 0, 0.613, 1.25, 2.5 and 5 mM, and the activity of compounds 3 and 4 was found to be higher than that of rosiglitazone at 1 mM and higher concentrations (Fig. 6 ).
Conclusion
To find novel PPAR ligands, we prepared several 2-nonylaminopyridine derivatives which were designed based on the structure of a PPARg ligand 1. In PPAR binding affinity assays, compound 4, which had an ethoxy group at the C-2 position of the propanoic acid of 1, showed high binding affinity for PPARg and little affinity for PPARa and PPARd. Compound 3, which had an ethyl group at the C-2 position of propanoic acid, was found to be a PPARa/g dual ligand.
Compound 6, the meta isomer of 1, has been shown to be a PPARa ligand. The introduction of methyl (7) and ethyl (8) groups at the C-2 position of the propanoic acid of 6 further improved PPARa-binding potency. In cell-based transactivation assay, compounds 3 and 4 showed dual-agonist activity toward PPARa and PPARg. Compound 6 was found to be a a) Compounds were screened for agonist activity on PPAR-GAL4 chimeric receptors in transiently transfected HEK-293 cells as described. EC 50 value is the molar concentration of the test compound that affords 50% of maximal reporter activity. 33) triple agonist and compound 8 proved to be a selective PPARa agonist. In the human hypodermic preadipocyte differentiation test, it was demonstrated that the activity of compounds 3 and 4 was higher than that of rosiglitazone. The findings of this study will help provide an effective agent for Type 2 diabetes and hyperlipidemia.
Experimental
Melting points were determined using a Yanagimoto micro melting point apparatus or a Büchi 545 melting point apparatus and were left uncorrected. Proton nuclear magnetic resonance spectra ( 1 H-NMR) were recorded on a JEOL JNM-LA500 spectrometer in solvent as indicated. Chemical shifts (d) were reported in parts per million relative to the internal standard tetramethylsilane. High-resolution mass spectra (HR-MS) were recorded on a JEOL JMS-SX102A mass spectrometer. Reagents and solvents were purchased from Aldrich, Tokyo Kasei Kogyo, Wako Pure Chemical Industries, and Kanto Kagaku, and used without purification. Flash column chromatography was performed using Silica Gel 60 (particle size 0.046-0.063 mm) supplied by Merck.
2-Nonylaminopyridine (18) To a solution of 2-bromopyridine (0.9 ml, 9.20 mmol) in 10 ml of anhydrous toluene were added n-nonylamine (17, 10.0 ml, 55.2 mmol), Pd 2 (DBA) 3 (0.169 g, 0.18 mmol), rac-BINAP (0.229 g, 0.37 mmol) and sodium tert-butoxide (1.24 g, 12.9 mmol). The reaction mixture was stirred at 105°C for 3 d under Ar, and poured into water. The whole was extracted with AcOEt. The AcOEt layer was separated, washed with water and brine, and dried over Na 2 SO 4 . The solvent was removed by evaporation in vacuo. Purification by silica gel flash chromatography (AcOEt/nhexaneϭ1/5) gave 1. 
4-(2-Bromoethoxy)benzaldehyde (20a)
To a solution of p-hydroxybenzaldehyde (19a, 1.25 g, 10.0 mmol) in 13 ml of THF were added Cs 2 CO 3 (4.28 g, 13.0 mmol) and 1,2-dibromoethane (1.76 ml, 20.0 mmol). The mixture was stirred at 65°C for 14 h. The mixture was poured into 2 N aqueous NaOH. The mixture was extracted with AcOEt. The AcOEt layer was separated, washed with water and brine, and dried over Na 2 SO 4 . The solvent was removed by evaporation in vacuo. Purification by silica gel flash chromatography (AcOEt/n-hexaneϭ1/3) gave 0.758 g (33%) of 21a as a light yellow solid: 1 
3-[4-(2-Bromoethoxy)phenyl]acrylic Acid Ethyl Ester (21a)
To a suspension of NaH (191 mg, 4.78 mmol) in 4 ml of anhydrous THF was added dropwise a solution of ethyl diethylphosphono acetate (1.07 ml, 5.21 mmol) in 5 ml of anhydrous THF at 0°C under Ar. The mixture was stirred for 1 h at 0°C. To the mixture was added dropwise a solution of 20a (916 mg, 4.00 mmol) in 8 ml of anhydrous THF. The reaction mixture was stirred for 16 h at 0°C. The reaction mixture was poured into ice-water and extracted with AcOEt. The AcOEt layer was separated, washed with brine, and dried over Na 2 SO 4 . The solvent was removed by evaporation in vacuo. Purification by silica gel flash chromatography (AcOEt/n-hexaneϭ1/5) gave 901 mg (76%) of 20a as a white solid: 
3-{4-[2-(Nonyl-pyridin-2-ylamino)ethoxy]phenyl}propanoic Acid Ethyl Ester (23a)
To a solution of 22a (0.343 g, 1.14 mmol) in 1 ml of THF were added 2-nonylaminopyridine (1.01 g, 4.56 mmol), KI (0.189 g, 1.14 mmol) and Et 3 N (0.45 ml, 2.30 mmol). The reaction mixture was stirred for 28 h at 105°C. The reaction mixture was poured into water and extracted with AcOEt. The AcOEt layer was separated, washed with water and brine, and dried over Na 2 SO 4 . Purification by silica gel flash chromatography 
2-{4-[2-(Nonylpyridin-2-ylamino)ethoxy]benzyl}butyric
Acid (3) Compound 3 was prepared from 19a using the procedure described for 1 in 2.5% yield. In the step of the synthesis of 21b, 2-(diethoxyphosphoryl)butyric acid ethyl ester was used instead of ethyl diethylphosphono acetate: colorless oil; 
2-Methyl-3-{3-[2-(nonylpyridin-2-ylamino)ethoxy]phenyl}propanoic Acid (7)
Compound 7 was prepared from 19b using the procedure described for 1 in 3.5% yield. In the step of the synthesis of 21e, 2-(diethoxyphosphoryl)propanoic acid ethyl ester was used instead of ethyl diethylphosphono acetate: light yellow oil; -3-{3-[2-(nonylpyridin-2-ylamino) ethoxy]phenyl}propanoic Acid (9) Compound 9 was prepared from 19b using the procedure described for 1 in 2.5% yield. In the step of the synthesis of 21g, {4-(2-Bromoethoxy)phenyl}methanol (24a) To a solution of 20a (890 mg, 3.89 mmol) in 10 ml of EtOH was added NaBH 4 (163 mg, 3.89 mmol). The reaction mixture was stirred for 6 h at room temperature. The reaction mixture was poured into water, and extracted with AcOEt. The AcOEt layer was separated, washed with water and brine, and dried over Na 2 Acetic Acid 4-(2-Bromoethoxy)benzyl Ester (25a) To a solution of 24a (2.31 g, 10.0 mmol) in 20 ml of CH 2 Cl 2 were added Ac 2 O (3.10 ml, 30.0 mmol) and a catalytic amount of DMAP. The reaction mixture was stirred for 1 d at room temperature and diluted with AcOEt. The AcOEt solution was washed with water and brine, and dried over Na 2 SO 4 . Purification by silica gel flash chromatography (AcOEt/n-hexane ϭ1/5) gave 2.62 g (96%) of 25a as a light yellow oil: 1 3-{4-(2-Bromoethoxy)phenyl}-2-methylpropionic Acid Methyl Ester (26a) To a solution of 25a (0.948 g, 3.47 mmol) and 1-methoxy-1-trimethylsilyloxypropene (1.00 g, 6.24 mmol) in 35 ml of anhydrous CH 2 Cl 2 was added magnesium perchlorate (0.129 g, 0.694 mmol) under Ar. The reaction mixture was stirred for 1 d at room temperature. The reaction mixture was diluted with CH 2 Cl 2 . The CH 2 Cl 2 solution was washed with water and brine, and dried over Na 2 SO 4 . The solvent was removed by evaporation in vacuo. Purification by silica gel flash chromatography (AcOEt/nhexaneϭ1/10) gave 0.935 g (90%) of 26a as a colorless oil:
2-Ethoxy

